Journal section: Oral Medicine and Pathology Publication Types: Research doi:10.4317/jced.56379 https://doi.org/10.4317/jced.56379

## Clinicopathologic data of individuals with oral lichen planus: A Brazilian case series

# Sara-Lia-Gonçalves de Lima <sup>1</sup>, José-Alcides-Almeida de Arruda <sup>2</sup>, Lucas-Guimarães Abreu <sup>3</sup>, Ricardo-Alves Mesquita <sup>4</sup>, Rejane-Faria Ribeiro-Rotta <sup>5</sup>, Elismauro-Francisco Mendonça <sup>5</sup>, Diego-Antônio-Costa Arantes <sup>5</sup>, Aline-Carvalho Batista <sup>5</sup>

<sup>1</sup> DDS, MSc Student, Department of Stomatology (Oral Medicine and Oral Pathology), School of Dentistry, Universidade Federal de Goiás, Goiânia, GO, Brazil

<sup>2</sup> DDS, MSc, PhD Student, Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

<sup>3</sup> DDS, PhD, Department of Pediatric Dentistry and Orthodontics, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

<sup>4</sup> DDS, PhD, Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

<sup>5</sup> DDS, PhD, Department of Stomatology (Oral Medicine and Oral Pathology), School of Dentistry, Universidade Federal de Goiás, Goiânia, GO, Brazil

#### Correspondence:

Departament of Stomatology (Oral Pathology) School of Dentistry, Universidade Federal de Goiás Praça Universitária, S/N, Setor Universitário Goiânia, GO, Brazil. CEP: 74605-220 ali.caba@uol.com.br

Received: 01/10/2019 Accepted: 04/11/2019 de Lima SLG, de Arruda JAA, Abreu LG, Mesquita RA, Ribeiro-Rotta RF, Mendonça EF, Arantes DAC, Batista AC. Clinicopathologic data of individuals with oral lichen planus: A Brazilian case series. J Clin Exp Dent. 2019;11(12):e1109-19.

http://www.medicinaoral.com/odo/volumenes/v11i12/jcedv11i12p1109.pdf

Article Number: 56379 http://www.medicinaoral.com/odo/indice.htm
© Medicina Oral S. L. C.I.F. B 96689336 - eISSN: 1989-5488
eMail: jced@jced.es
Indexed in:
Pubmed
Pubmed Central® (PMC)
Scopus
DOI® System

### Abstract

Background: The aim of the present series was to analyze the sociodemographic characteristics, clinicopathologic features, and oral health-related quality of life of 41 individuals with oral lichen planus (OLP).

Material and Methods: In a retrospective analysis (1998-2018), individuals with a clinical diagnosis of OLP from a referral service of Oral Medicine of Brazil were invited for follow-up. The individuals were assessed using the Oral Health Impact Profile-14 (OHIP-14) form. Histopathological data were reviewed according to the latest criteria proposed by the American Academy of Oral and Maxillofacial Pathology (AAOMP/2016).

Results: This series mainly consisted of females (70.7%) in their forties (31.7%). The buccal mucosa (68.2%) was the most commonly affected site. Reticular (56.1%) and erosive (34.3%) appearances were the most frequent. According to OHIP-14, individuals with OLP at multiple sites in the oral cavity showed worse values in the handicap domain and those who did not respond to corticosteroids showed a higher score on the psychological discomfort domain.

Conclusions: The findings of the present study, using the AAOMP/2016 criteria, agree with case series and retrospective studies reported in the literature. Besides, OLP in its more severe clinical forms had an influence on patient quality of life.

Key words: Diagnosis, epidemiology, oral lichen planus, oral mucosa, quality of life.

## Introduction

The first clinical characterization of oral lichen planus (OLP) was described by Dr. Erasmus Wilson in 1866 (1) as a nonscrapable white plaque found in the buccal mucosa, especially in middle-aged women. Later, in 1895, Louis Wickham added to this description a pattern of interlaced white striae, which were then called Wickham striae (2). Over a period of 40 years, OLP was studied and diagnosed only in terms of its clinical characteristics, since microscopic findings were only defined for diagnosis in 1906 by M. William Dubreuilh (3).

Approximately 15% of individuals with OLP may also exhibit skin lesions (4). OLP individuals may be asymptomatic or may suffer extreme degrees of pain with a possible impact on their quality of life (5,6). OLP generally affects the buccal mucosa, gingiva, and tongue, manifesting in the form of bilateral and symmetric lesions with a reticular pattern, with the erosive, atrophic, bullous and plaque-like types being accepted only in the presence of reticular lesions (7). The American Academy of Oral and Maxillofacial Pathology (AAOMP/2016) (5) proposed a modification in the clinical and morphological criteria described by the World Health Organization in 1978 (7), and reviewed by van der Meij and van der Waal in 2003 (8), characterizing OLP as white or red lesion, multifocal, of symmetric distribution, being classified as reticular/papular, atrophic (erythematous), erosive (ulcerative), plaque and bullous (5). In addition, classical histopathological characteristics such as the presence of an infiltrate predominantly consisting of lymphocytes distributed as a band in the subepithelial region, lymphocyte exocytosis and basal keratinocyte liquefaction have been well established and, according to the AAOMP/2016, should be associated with the clinical characteristics for a final diagnosis (5).

This inflammatory disease of an autoimmune nature regulated by T lymphocytes affects approximately 2% of the world population, mainly occurring in women aged 30 to 80 years with mean of 52 years (3,5). Its etiopathogeny is still unknown and patient treatment has been limited only to symptom relief with topical or systemic corticosteroids (9,10). A relationship between autoimmune diseases and stress, anxiety and depression is described in some studies (11,12) and, among these diseases, a possible relationship has been reported between emotional changes and the manifestation of OLP with an impact on the quality of life of individuals (6,11,13,14). The Oral Health Impact Profile-14 (OHIP-14) is used to measure the quality of life of individuals with OLP or with other autoimmune diseases affecting the oral region (13-15). The results obtained have pointed out the importance of this instrument for the understanding of the impact of autoimmune diseases on quality of life; however, few studies using OHIP-14 for these diseases have been conducted on the Brazilian population (15).

Although the clinical and morphological characteristics of OLP are well defined, there is a challenge in its histopathological diagnosis due to the lack of clinical data submitted to oral and maxillofacial pathology services, with an increased risk of confusion with other lesions, such as oral leukoplakia, frictional keratosis and lichenoid reaction (5,16). Case series studies of Asian, American, European and Oceanic populations have reported epidemiological data of individuals with OLP (17-20). However, few investigations have described the occurrence and clinicopathologic features of these lesions in Brazil (21-23). Therefore, the purpose of the present study was to report 41 cases of OLP according to the clinicopathologic criteria proposed by AAOMP/2016. In addition, the patients were invited to engage in follow-up and were evaluated by OHIP-14 in order to correlate the clinical features of the disease with the quality of life of these affected individuals.

#### **Material and Methods**

#### -Case series and ethical issues

A retrospective analysis was conducted on 41 individuals with OLP. The guidelines proposed to strengthen the description of observational studies (STROBE) were followed (24). The present study consisted of individuals who had been referred to the service of Oral and Maxillofacial Pathology and Oral Medicine (CGDB) of School of Dentistry of Universidade Federal de Goiás (UFG), Goiânia, Brazil between 1998 and 2018. During this 20-year period, the participants had been evaluated and clinical information had been compiled by various providers with experience in oral diagnosis. The study was approved by the Ethics Committee on Human Research of the institution (No. 3.095.226). According to the Statement of Helsinki, the participants agreed with the publication of their cases.

## -Data collection

The case series is reported according to the flow diagram presented in Figure 1. The demographic data (age and sex) of the selected subjects were obtained by an active survey and evaluation of the medical records in the archives of the service. The clinical data recorded were also evaluated in terms of the aspect of the lesions: ulceration, whitish striae, and white plaques. The lesions were then classified as reticular, erosive, atrophic or bullous. Also, were divided into groups according to their distribution as follows: lesion in only single bilateral/ symmetric site and multiple bilateral/symmetric sites. The following anatomical locations were possible: buccal mucosa, tongue, lips, gingiva, and palate. Regarding patient treatment, two therapeutic modalities were established: mouthwash/oral use of dexamethasone, 0.1 mg/ mL, 12/12 hours and topical application of triamcinolone acetonide, 1 mg/g, 8/8 hours. Data about lesion recurrence were collected and the following groups were defined according to time of recurrence: lesions recurring after 0-1 month, 2-3 months, 4-6 months, one year, and more than one year (Table 1).

In order to confirm the diagnosis of OLP, the records of the clinical and histopathological parameters of the individuals were reviewed according to the criteria proposed by AAOMP/2016 (5). Clinically, lesions with a confirmed diagnosis of OLP had to be obligatorily symmetric and multifocal, consisting of the exclusively reticular form or of the atrophic, erosive, bullous and/or plaque forms. The histopathological records of all participants from the Oral Pathology service of the UFG were also reviewed in order to microscopically confirm the cases of OLP. Four consultants (A.C.B., E.F.M., D.A.C.A., and R.A.M.) in Oral and Maxillofacial Pathology and Oral Medicine assisted with the ratification of the cases. The exclusion criteria were: missing information regarding sociodemographic data and the clinicopathologic characteristics of the disease, the presence of unilateral lesions without an ulcerated, whitish, atrophic or bullous aspect, lesions in contact with amalgam or prosthetic materials or a history of tobacco, alcohol or cinnamon use.

The histopathological data were supposed to show a predominantly lymphocytic infiltrate arranged in a band and located on the lamina propria, with destruction/liquefaction of basal keratinocytes, lymphocyte exocytosis, and absence of epithelial dysplasia (5). Exclusion criteria are shown in Figure 1.

In addition, to confirmatory and illustrative purposes, the immunohistochemical analyses for recognition of CD8+ T lymphocytes (clone C8/144B; Dako, Carpinteria, CA, USA; 1:200) was accomplished in all samples. The sections were treated with the Kit Novolink<sup>TM</sup> Max Polymer Detection System (Novocastra, Leica Biosystems Gmb, Wetzlar, HE, Germany) and the reactions were developed with 3.3'-diaminobenzidine (DAB, Dako, Carpinteria, CA, USA).

-OHIP-14 questionnaire

The OHIP-14 questionnaire, first developed in English, was adapted and validated for Brazilian Portuguese (25) and was used for the assessment of the impact of oral conditions on patient quality of life. The questionnaire contains 14 questions divided into seven domains: functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability, and handicap. Five response options are available for each question, with the following scores: 'never'=0, 'hardly ever'=1, 'sometimes'=2, 'fairly often' = 3, 'very often' = 4. The total score ranges from 0 to 56 points. The higher the score, the greater the negative perception of the patient regarding the impact of his oral conditions on his quality of life. Scores for the seven domains were also possible (25). The patients were invited by telephone to engage in follow-up and were evaluated by OHIP-14.

 Table 1: Demographic data and clinical features of the cases of oral lichen planus.

Variable	n (%)
Gender	
Male	12 (29.3)
Female	29 (70.7)
Age (decades of life)	
20-29	4 (9.7)
30-39	9 (21.9)
40-49	13 (31.7)
50-59	10 (24.6)
60-69	4 (9.7)
70-79	1 (2.4)
Clinical appearance	
Reticular	23 (56.1)
Erosive	14 (34.3)
Atrophic	2 (4.8)
Bullous	2 (4.8)
Distribution of lesions	
Single bilateral/symmetric	22 (53.6)
Multiple bilateral/symmetric	19 (46.4)
Anatomical location <sup>a</sup>	
Buccal mucosa	28 (68.2)
Tongue	15 (36.5)
Lip	12 (29.2)
Gingiva	8 (19.5)
Palate	4 (9.7)
Symptoms	
Symptomatic	23 (56.1)
Asymptomatic	18 (43.9)
Treatment $(n=31)^b$	
Dexamethasone	23 (56.1)
Triamcinolone acetonide	8 (19.5)
Response to treatment (n=31)	
Positive	10 (32.3)
No therapeutic response	21 (67.7)
Recurrence (n=27)	
0-1 month	9 (33.3)
2-3 months	6 (22.2)
4-6 months	8 (29.6)
1 year	1 (3.8)
More than 1 year	3 (11.1)
Follow-up period $(n=27)$ (months)	Mean 10.6±25.1

<sup>a</sup> This variable was not analyzed in terms of number of individuals, but rather in terms of number of lesions presented.

<sup>b</sup> Ten patients were followed up and received no corticotherapy.




Fig. 1: Sample selection flowchart.

#### -Statistical analysis

Data were analyzed statistically using the Statistical Package for the Social Sciences (SPSS, SPSS Inc., version 23.0, Armonk, USA). A descriptive analysis was carried out using the absolute and relative values of the clinicodemographic data collected. The sample was divided into groups according to the characteristics of the lesions, i.e., clinical type (reticular and erosive), location (a single bilateral site and multiple bilateral sites), and according to the response to topical or systemic corticotherapy (positive or no response). The Shapiro-Wilk test was used to determine the normality of the OHIP-14 scores and the Mann-Whitney test was used to compare the groups regarding the OHIP-14 domains. The level of significance was set at 5% in all analyses.


#### Results

#### -Case series


Forty-one individuals were considered to have a definitive diagnosis of OLP according to the clinical and histopathological criteria established by the AAOMP/2016 (Figs. 1-3), representing about 0.33% of the individuals whose biopsy specimens (n=12088) were analyzed by the laboratory of Oral and Maxillofacial Pathology between 1998 and 2018.

Women were more affected (n=29; 70.7%) than men (n=12; 29.3%). Patient age ranged from 22 to 72 years, with mean age being  $45\pm13.6$  years for women and  $42\pm13.6$  years for men (Table 1). The reticular (n=23, 56.1%) and erosive (n=14, 34.3%) types were the most frequent. OLP affected different regions, the buccal mucosa being the most frequently affected site (n=28 lesions, 68.2%). Clinical manifestations at a single bilateral and symmetric lesion occurred in 51.9% (n=22) of the individuals, and symmetric lesions at multiple sites of the buccal mucosa occurred in 46.4% (n=19) of the patients (Table 1, Fig. 2).

Regarding symptomatology, there were 23 cases of symptomatic OLP with pain (56.1%); of these 88.9% exhibited the atrophic/erosive/bullous type. Therapy with a dexamethasone mouthwash (0.1 mg/mL; 12/12 hours) was implemented in all symptomatic cases and topical treatment with triamcinolone acetonide (1 mg/g; 8/8 hours) was prescribed for asymptomatic patients (n=8, 19.5%). Of the 31 medicated patients, 21 did not improve with the medication (67.7%). Data regarding recu-



**Fig. 2:** Clinical aspects of reticular oral lichen planus at multiple symmetric bilateral sites. (A, B) Interlaced white lines forming striae (Wickham striae) located in the right and left jugal mucosa. (C, D) Whitish lines located in the upper and lower gingiva.



**Fig. 3:** Oral lichen planus exhibiting lymphocytic infiltrate arranged in a band and located in the lamina propria, with destruction of basal keratinocytes, lymphocyte exocytosis, and absence of epithelial dysplasia (A-C). Photomicroscopes images illustrate predominantly CD8+ lymphocytes in the inflammatory infiltrate (D-F). Hematoxylin and eosin:  $A = 5 \times$ ,  $B = 10 \times$  and  $C = 20 \times$ ; Immunohistochemistry:  $D = 5 \times$ ,  $E = 10 \times$  and  $F = 20 \times$ .

rrence of the lesions were obtained for 27 patients, with nine of them (33.3%) suffering a relapse within up to one month after the initial visit and the others with two months to more than one year. The mean follow-up was of  $10.6\pm25.1$  months (range: 1-96 months) (Table 1). -Quality of life (OHIP-14)

Thirteen of the patients with a definitive diagnosis of OLP (31.7%) came to the CGDB for clinical evaluation and filling of the questionnaire; 53.8% (n=7) of them having the reticular clinical type and 46.2% (n=6) the erosive type. Patients with the erosive clinical type of OLP, with multiple symmetric/bilateral and with no response to corticotherapy had higher values in the functional limitation, pain and discomfort domains. Social disability was worse in patients with multiple symmetric/bilateral lesions (Table 2).

Comparison of the groups revealed that patients with OLP at multiple symmetric/bilateral sites had worse scores for the total disability domain than patients with lesion at a single bilateral site (p=0.03). In addition, pa-

tients who did not respond to corticotherapy for OLP symptoms had significantly worse results in the psychological discomfort domain than patients who responded to corticotherapy (p=0.04). The results obtained for the remaining domains were similar for all groups (p>0.05) (Table 2).

## Discussion

Clinicians, maxillofacial surgeons and oral and maxillofacial pathologists face a constant challenge in the diagnosis of OLP since the clinical and microscopic characteristics of the condition are similar to those of other diseases such as oral leukoplakia, oral frictional hyperkeratosis, oral pemphigus, and mainly oral lichenoid reaction (5,11,16). Other factors that appear to influence the diagnosis of OLP are the varied clinical forms of the disease, i.e., reticular, erosive, atrophic, bullous, the multiple anatomical regions affected, the still undefined etiopathogenesis, as well as the histopathological characteristics, which are influenced by disease activity at

Table 2: Mean scores of OHIP subscales according to the clinical features of oral lichen planus, anatomical location and corticotherapy.

<b>Clinical features</b>				Variables	\$			
Lesion	Functional limitation	Pain	Psychological discomfort	Physical disability	Psychological disability	Social disability	Handicap	Overall score
Reticular (n=7)	0.0	1.0	6.0	0.0	1.0	2.0	2.0	12.0
Erosive (n=6)	2.5	5.0	12.0	0.0	3.0	2.0	2.5	19.5
<i>p</i> -value	0.11	0.09	0.50	0.1	0.16	0.69	0.49	0.07
Number of lesions								
One site (bilateral in the buccal mucosa) (n=7)	0.0	0.5	4.0	0.0	2.0	0.0	2.0	12.0
More than one site (bilateral in the buccal mucosa) and others (n=6)	0.5	3.0	6.0	0.0	2.5	2.0	3.0	16.5
<i>p</i> -value	0.75	0.24	0.08	1.00	0.66	0.07	0.03*	0.05
Corticotherapy								
Positive (n=5)	0.0	2.0	5.0	0.0	3.0	2.0	3.0	13.0
No therapeutic response (n=8)	0.5	2.5	6.0	0.0	2.5	2.0	2.0	15.5
<i>p</i> -value	0.55	1.00	0.04*	0.61	0.21	0.18	0.39	0.40

\*Statistically significant (p<0.05, Mann-Whitney test).

the time when a biopsy is taken (5,11). Cheng *et al.* (5) have reported that probably no other disease in the oral and maxillofacial pathology field has caused such controversy and debate regarding its diagnosis as OLP, underscoring the importance of the association of clinical and microscopy data for the investigators.

The present case series revealed that OLP was more frequent among women in their forties, with presentation in the reticular form and with lesions in the buccal mucosa. Worldwide studies of individuals with OLP have reported similarities in the clinical and demographic profile as demonstrated in Table 3, 3 continue, 3 continue-1, 3 continue-2. These results may be of aid for clinicians within the context of OLP identification, since the diagnostic hypothesis could be raised according to this clinical and demographic profile. However, according to the criteria established by the AAOMP/2016 (5), the presence of specific clinical and microscopic parameters is necessary for a definitive diagnosis of OLP, and these parameters should be correlated at the time of diagnosis. In contrast to previously published studies (21-23), the present report is the first Brazilian survey to use the parameters established by the AAOMP/2016 for a final diagnosis of this condition.

Herein, 88.9% of the cases with painful symptoms were of the erosive type. This was also observed in other studies, in which OLP cases showed features ranging from no symptoms to mild burning sensations and to extreme pain degrees observed in the erosive form (5,11).

Dexamethasone and triamcinolone were the treatments used in the present study. Of the 31 patients treated, 67.7% did not respond to the medication, demonstrating the need for a more effective treatment of OLP since the fact that its etiopathogeny has not been fully elucidated only permits treatment limited to the relief of symptoms with the use of local or systemic immunosuppressors (4,5,9,11,26). Although the treatment of asymptomatic individuals is a controversial issue and, to date, does not have guidelines that contribute to clinical decision making, individuals with eritroplasic lesions are medicated preventively in order to offer greater comfort (5,26).

In this study, there was no case of malignant transformation; however, despite doubts about the potential for malignant transformation of OLP, systematic reviews have detected that the rate of such occurrence ranges from 0 to 3.5% and the overall rate of transformation is 1.09% (27-29).

In view of the clinical implications of OLP, quality of life has been increasingly recognized as an important indicator of the need for more effective treatments. As an example, Karbach *et al.* (13) used OHIP-14 and concluded that the life of patients with symptomatic OLP who did not respond to corticotherapy was more affected by the disease. In agreement with the present findings, Alves *et al.* (12) observed that, as a consequence of long

Author(s)/year of	Country	Cases	Mean age	Ge	Gender	Histopathologi-	Most prevalent	Most prevalent	Follow-	Malignant	Diagnostic
publication			(range)	Male	Female	cal analysis	clinical appearance	location	up (mean)	transformation (n)	criteria
Pindborg et al., 1976	India	118	NI (35-64)	54	64	Some cases	IN	Buccal mucosa; tongue	IN	IN	IN
Thorn et al., 1988	Denmark	611	53 (NI)	202	409	Yes	Reticular	IN	7.5 y	IN	IN
Salem, 1989	Saudi Arabia	72	IN	40	32	Yes	Atrophic- erosive	Buccal mucosa, gingiva, tongue	3.2 y	4	Shafer et al., 1974
Silverman <i>et al.</i> , 1991	USA	214	54 (21-83)	62	152	Yes	Erosive	Buccal mucosa, gingiva, tongue	7.5 y	5	IN
Bagán-Sebastián <i>et</i> al., 1992	Spain	205	50.6 (NI)	41	164	IN	Reticular	Buccal mucosa, tongue, gingiva	IN	IN	IN
Gorsky et al., 1996	Israel	157	52.5 (22-89)	62	95	Yes	Reticular	Buccal mucosa; gingiva, tongue	IN	2	IN
Chainani-Wu <i>et al.</i> , 2001	USA	229	55 (NI)	75	154	Some cases	Erosive	Buccal mucosa	IN	4	IN
Laeijendecker <i>et al.</i> , 2005	Netherlands	200	53 (25-83)	68	132	Yes	Hyperkeratotic	Buccal mucosa, tongue, gingiva	10 y	3	IN

2

č

Xue <i>et al.</i> , 2005	China	674	50.4 (10-78)	230	444	Yes	Reticular	Buccal mucosa, lip, tongue	IN	4	WHO/1978 van der Meij and van der Waal
Ingafou <i>et al.</i> , 2006	UK	069	52 (16-83)	251	439	Some cases	Reticular	Buccal mucosa, alveolar ridge, tongue	IN	13	IN
Torti et al., 2007	USA	50	60 (41-80)	15	35	Yes	Erosive	IN	27 y	IN	IN
Carbone <i>et al.</i> , 2009	Italy	808	61.4 (NI) for women	315	493	Yes	Reticular and plaque	Buccal mucosa, tongue, gingiva	44.8 mo (for women)	15	WHO/1978 van der Meij and van der Waal
Paketfrat <i>et al.</i> , 2009	Iran	420	41.6 (13-75)	147	263	Yes	Reticular	Buccal mucosa, tongue, gingiva	IN	£	IN
Kesić <i>et al.</i> , 2009	Serbia	163	53.9 (NI)	49	114	Yes	Reticular	IN	IN	2	IN
Alves et al., 2010	Brazil	110	53.8 (22-97)	26	84	Some cases	Reticular	Cheek mucosa, tongue, gingiva	IN	IN	IN
Bajaj <i>et al.</i> , 2010	Pakistan	95	NI (17-62)	40	55	Some cases	Reticular	Buccal mucosa, tongue, gingiva	IN	IN	WHO/1978 van der Meij and van der Waal
Bermejo-Fenoll et al., 2010	Spain	550	56.3 (14-91)	128	422	Yes	Atrophic and erosive	Cheek mucosa, tongue, gingiva	IN	5	WHO/1978
Kumar and Hay, 2010	New Zeeland	267	57 (21-93)	82	185	Yes	IN	IN	IN	IN	IN
Torrente-Castells <i>et</i> <i>al.</i> , 2010	Spain	65	59 (16-88)	25	40	Yes	White form	Buccal mucosa, tongue, gingiva	18.2 mo	2	WHO/1978 van der Meij and van der Waal
Thongprasom <i>et al.</i> , 2010	Thailand	533	50.9 (17-90)	104	429	Yes	Atrophic	Buccal mucosa, gingiva, mucobuc- cal fold	IN	1	Consensus meeting in Chamonix in 2003
Fernandez-Gonzalez <i>et</i> <i>al.</i> , 2011	Spain	50	56 (22-82)	11	39	Yes	Reticular	Buccal mucosa, tongue	IN	IN	IN
Kaplan <i>et al.</i> , 2012	Israel	171	59.1 (28-90)	51	120	Yes	Hyperkeratotic; atrophic and erosive	Buccal mucosa, tongue, gingiva	4.3 y	10	WHO/1978 van der Meij and van der Waal
Aminzadeh <i>et al.</i> , 2013	Iran	187	46.9 (NI)	IN	IN	Yes	IN	Buccal mucosa, gingiva, tongue	IN	IN	IN

e1116

10         260         Yes         Red form         Buceal mucosa, ongue, gingiva,         NI         1           79         49         Some cases         Reticular         Buceal mucosa, gingiva, tongue         6 mo         0           135         498         Yes         White (reticular pupular and pupular and pupular and pupular and         Buceal mucosa, gingiva, tongue         NI         6           135         498         Yes         White (reticular pupular and pupular and	Table 3 continue-1: Studies of oral lichen planus lesions in different	ies of oral lichen	1 planus le	sions in different		geographic regions of the world.	the world.					
13India136 $36.9$ (N1)7949Some casesRetricularBaced mucosa, gugvi, ungue, gugvi, ungue,6mo013Romania633 $22$ (N1)135498YeisWhite (reticular, pupping and pupping and pupping and pupping and gugvi, ungue,Buced mucosa, gugvi, ungue,N1613Romania533 $22$ (N1)135498YeisWhite (reticular, pupping and pupping and pupping and pupping andBuced mucosa, gugvi, ungue,N1N1 $eral/$ Anstralia323Anstralia, sof (22-36)53144Some casesReticularBuced mucosa, gugvi, ungue,N1N1 $craliand Crania323Sutuary149Home casesReticularBuced mucosa,gugvi, ungue,N1N1craliand Crania323Sutuary149Some casesReticularBuced mucosa,gugvi, ungue,N1N1craliand Crania323Sutuary149Some casesReticularBuced mucosa,gugvi, ungue,N1N1cralibucia5623-74924YeisBuced mucosa,gugvi, ungue,N1N1cralibucia5353-5749YeisYeisBuced mucosa,gugvi, ungue,N1N1cralibucia5353-749YeisYeisBuced mucosa,gugvi, ungue,N1N1craliEcopia5353-74$	Gümrü, 2013	Turkey	370	49.8 (16-83)		260	Yes	Red form	Buccal mucosa, tongue, gingiva	IN	-	WHO/1978 van der Meij and van der Waal
13Romania6332 (N1)135498YeaWise frectudar, papatasBuccal mucosa, papatasN16 <i>et al.</i> and Croatia3290,414-0382.38Some casesReticularBuccal mucosa, gugav, uogaeN18 <i>et al.</i> and Croatia3290,414-038144Some casesReticularBuccal mucosa, gugav, uogaeN1N10.14Croatia56388 (11-34)149V44Some casesReticularBuccal mucosa, gugav, uogae76 y40.15Social56388 (11-34)149Some casesReticularBuccal mucosa, gugav, uogae76 y40.16Croatia56388 (11-34)19V149Some casesReticularBuccal mucosa, gugav, uogaeN1N10.15Barzil37533 (27-34)9238V65Buccal mucosa, gugav, uogaeN1N1N10.16Fespar76V75Buccal mucosa, gugav, uogaeN1N1N1N10.16Fespar76V75Buccal mucosa, gugav, uogaeN1N1N1N10.16Fespar233 (27-34)724Some casesReticularBuccal mucosa, gugav, uogaeN1N10.16Fespar56FesparN1N1N1N1N1N1N10.17Fespar5123 (27-39)724Some casesReti	Munde <i>et al.</i> , 2013	India	128	36.9 (NI)	79	49	Some cases	Reticular	Buccal mucosa, gingiva, tongue	6 то	0	WHO/1978 van der Meij and van der Waal
<i>et al.</i> Australia3.23Mastralia8.52.381.382.381.382.381.381.381.381.381.381.381.381.391.311.	Tovaru <i>et al.</i> , 2013	Romania	633	52 (NI)	135	498	Yes	White (reticular, papular and plaque)	Buccal mucosa, tongue, gingiva	IN	9	van der Meij and van der Waal
	Vučićević Boras <i>et al.</i> , 2014	Australia and Croatia	323	Australia: 59.9 (34-92) Croatia: 56 (22-85)	85	238	Some cases	Reticular	Buccal mucosa, gingiva, tongue	IN	IN	IN
.2014Czech Re- public17155.2 (20-83)55166YesReticularBuccal mucosa, gingiva, tongueNI0015Brazil37373 (32-74)928YesErosiveBuccal mucosa, gingiva, tongueNININI015India100396 (19-69)7129YesFrosiveBuccal mucosa, gingiva, tongueNININI015India100396 (19-69)7129YesNINININI016Egypt6448.7 (NI)2044Some casesRed OLP (atro- gingiva, tipsBuccal mucosa, gingiva, tipsNI20015Brazil2158.8 (NI)7144Some casesReticularBuccal mucosa, gingiva, tipsVI20016Brazil215158.8 (NI)714Some casesReticularBuccal mucosa, gingiva, tipsVI20016Itan11244.5 (15-86)3973YesErosiveBuccal mucosa, gingiva, tipsVI102016Itan11244.5 (15-86)3973YesErosiveBuccal mucosa, gingiva, tipsVI112016Itan872973YesErosiveBuccal mucosa, gingiva, tipsNI112016Itan8797YesErosiveBuccal mucosa, gingiva, tipsNI112016Itan87	Budimir <i>et al.</i> , 2014	Croatia	563	58 (11-94)	149	414	Some cases	Reticular	Buccal mucosa, gingiva, tongue	7.6 y	4	WHO/1978
J15Brazil3733.(32.74)928YesFrosiveBucell mucosa, gingiva, iongueNINI2015India10039.(19.69)7129YesNININI02015India10039.(19.69)7129YesNININI0med,Egypt6448.7 (N1)2044Some casesRedOLP (atro- phic, erosive)Buceal mucosa, gingiva, ipsNI20ned,Egypt6448.7 (N1)7074Some casesRedOLP (atro- phic, erosive)Buceal mucosa, gingiva, ipsNI20nos1ran12158.8 (N1)7374Some casesRetoularBuceal mucosa, gingiva, ips43NI1ran11241.5 (15.86)3973YesBrosineBuceal mucosa, gingiva43NI2016Itan11244.5 (15.86)3973YesBrosineBuceal mucosa, gingivaNI12016Itan11281.5 (15.86)3973YesBrosineBuceal mucosa, gingivaNI12016Itan11281.5 (15.86)3973YesBrosineBuceal mucosa, gingivaNI12016Itan11281.5 (15.86)3973YesProveBuceal mucosa, gingivaNI12016Itan11281.5 (15.86)3156YesProve<	Radochová <i>et al.</i> , 2014	Czech Re- public	171	55.2 (20-85)	55	116	Yes	Reticular	Buccal mucosa, tongue, alveolar ridge	IN	0	WHO/1978 van der Meij and van der Waal
2015         India         100 $39.6(19-6)$ 71 $29$ Yes         NI         NI         NI         NI         0           med,         Egypt $64$ $48.7(N1)$ $20$ $44$ Some cases $Red OLP (atro-gingiva, lips)         NI 2           015         Brazil         21 88(N1) 7 14         Some cases         Red OLP (atro-gingiva, lips)         NI 2           015         Brazil         21 58.8(N1) 7 14         Some cases         Red OLP (atro-gingiva, lips)         NI 2           015         Brazil         21 58.8(N1) 7 14         Some cases         Red OLP (atro-gingiva, lips)         NI 2 016         Iran         112 44.5(15-86) 39 73         Yes         Erosive         Buceal mucosa, Ri         NI 1 1ran         112 44.5(15-86) 39 73         Yes         Erosive         Buceal mucosa, Ri         NI 1 2016         Italus         87         Yes         $	Barbosa <i>et al</i> ., 2015	Brazil	37	53.3 (32-74)	6	28	Yes	Erosive	Buccal mucosa, gingiva, tongue	IN	IN	van der Meij and van der Waal
med,Egyt6448.7 (N1)2044Some casesRed OLP (atro- phic, erosive)Bucal mucosa, gingiva, lipsNI2015Brazil2158.8 (N1)714Some casesReticularBucal mucosa, tongue, gingiva4 yNI7015Brazil2158.8 (N1)714Some casesReticularBucal mucosa, tongue, gingiva4 yNI1016Itan11244.5 (15-86)3973YesErosiveBucal mucosa, gingivaNI112016Italy8759.2 (27-93)3156YesHyperkeratotic gingivaBucal mucosa, gingivaNI112016India12NI4373YesReticularBucal mucosa, gingivaNI12016India122NI4373YesReticularBucal mucosa, gingivaNINI2016India122NI4373YesReticularBucal mucosa, gingivaNINI	Hiremath et al., 2015	India	100	39.6 (19-69)	71	29	Yes	IN	NI	NI	0	Hiremath et al
015Brazil2158.8 (NJ)714Some casesReticularBuccal mucosa, tongue, gingiva4 yNI111244.5 (15-86)3973YesErosiveBuccal mucosa, gingivaNI120161taly8759.2 (27-93)3156YesHyperkratoticBuccal mucosa, gingivaNI112016Italy12NI4373YesBuccal mucosa, gingivaNI112016Italy122NI4379YesReticularBuccal mucosa, tongue, gumsNI112016Italia122NI4379YesReticularBuccal mucosa, tongue, gumsNININI	Mostafa and Ahmed, 2015	Egypt	64	48.7 (NI)	20	44	Some cases	Red OLP (atro- phic, erosive)	Buccal mucosa, gingiva, lips	IN	2	WHO/1978 van der Meij and van der Waal
IranI1244.5 (15-86)3973YesErosiveBuccal mucosa,NI12016Italy8759.2 (27-93)3156YesHyperkeratoticBuccal mucosa,NI12016Italy8759.2 (27-93)3156YesHyperkeratoticBuccal mucosa,NI12016Italy8759.2 (27-93)3179YesReticularBuccal mucosa,NI1	Werneck et al., 2015	Brazil	21	58.8 (NI)	7	14	Some cases	Reticular	Buccal mucosa, tongue, gingiva	4 y	IN	van der Meij and van der Waal
Italy8759.2 (27-93)3156YesHyperkeratoticBuccal mucosa,NI1India122NI4379YesReticularBuccal mucosa,NINI	Irani <i>et al.</i> , 2016	Iran	112	44.5 (15-86)	39	73	Yes	Erosive	Buccal mucosa, gingiva	IN	1	WHO/1978 van der Meij and van der Waal
India 122 NI 43 79 Yes Reticular Buccal mucosa, NI NI NI tongue	Lauritano <i>et al.</i> , 2016	Italy	87	59.2 (27-93)	31	56	Yes	Hyperkeratotic	Buccal mucosa, tongue, gums	IN	1	van der Meij and van der Waal
	Varghese et al., 2016	India	122	IN	43	79	Yes	Reticular	Buccal mucosa, tongue	IN	IN	van der Meij and van der Waal

Table 3 continue-2: Studies of oral lichen planus lesions in different	lies of oral licher	n planus le	sions in differen	t geograph	geographic regions of the world.	the world.					
Bandyopadhyay <i>et al.</i> , 2017	India	143	IN	78	65	Yes	Reticular	Buccal mucosa	IN	2	WHO 1978
Rimkevičius <i>et al.</i> , 2017	Lithuania	136	IN	25	111	Some cases	Reticular	Buccal mucosa, gingiva, tongue	4 y	3	IN
Park et al., 2018	Korea	113	49.5 (31-91)	79	34	Some cases	IN	Buccal mucosa, vestibule, tongue	2.24 y	IN	IN
Boñar-Alvarez <i>et al.</i> , 2019	Spain	59	NI (30-81)	23	36	Yes	Red OLP (ero- sive, ulcerative, atrophic)	Buccal mucosa, tongue, gingiva	IN	IN	van der Meij and van der Waal
Parlatescu <i>et al.</i> , 2019	Romania	80	60.1 (NI)	16	64	Yes	Keratotic	IN	IN	IN	van der Meij and van der Waal
mo, month(s); NI, not informed; OLP, oral lichen planus; USA, United States of America; UK, United Kingdom; WHO, World Health Organization; y, year(s)	ormed; OLP, ora	I lichen pl	anus; USA, Unite	ed States c	of America; U	K, United Kingdo	m; WHO, World He	alth Organization; y, yea	ır(s).		

and unsuccessful treatment, patients with OLP become emotionally unstable and their quality of life is affected. In addition, on the basis of our OHIP-14 findings, we observed that patients with lesions at multiple symmetric/bilateral sites and with the erosive clinical type of the disease had worse scores in the functional limitation, physical pain, psychological discomfort, psychological disability, and mainly total disability domains compared to patients with lesions at a single bilateral site and with the reticular clinical type. These results suggest that the number and the clinical type of these lesions have a negative impact on the life of the patients in terms of their concerns, social interaction and performance of daily activities, as demonstrated by Zucoloto et al. (11), who reported that the severity of OLP was proportional to its impact on quality of life in a Brazilian case series. However, large case series are needed in order to reinforce our findings.

The present investigation has some limitations that should be recognized. The first regards the sample size and the low response rate in the follow-up. The second is the retrospective nature of the study. Another limitation was the lack of a group of individuals without OLP. The presence of a control group would have become the assessment of the impact of OLP on quality of life more realistic. Finally, the diagnosis of OLP by immunofluorescence (16) was not carried out herein due to its high cost and to the fact that the sample mostly consisted of individuals referred by public health services, where treatment fees are not required.

#### Conclusions

In summary, middle-aged female patients with a reticular clinical presentation and lesions in the buccal mucosa were more frequent in this case series, in agreement with the literature. It is important to demonstrate that the standardization and association of clinical and histopathological criteria are important for the diagnosis, and mainly for a safe treatment of patients with this disease. In addition, the more severe clinical forms of the disease that did not respond to drug therapy seem to have a negative impact on the quality of life of the patients, thus further supporting the need for the implementation of other treatments of OLP.

#### References

1. Scully C, el-Kom M. Lichen planus: review and update on pathogenesis. J Oral Pathol. 1985;14:431-58.

2. Steffen C, Dupree ML. Louis-Frédéric Wickham and the Wickham's striae of lichen planus. Skinmed. 2004;3:287-9.

3. Au J, Patel D, Campbell JH. Oral lichen planus. Oral Maxillofac Surg Clin North Am. 2013;25:93-100.

4. Al-Hashimi I, Schifter M, Lockhart PB, Wray D, Brennan M, Migliorati CA, et al. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103Suppl:S25.e1-12.

5. Cheng YS, Gould A, Kurago Z, Fantasia J, Muller S. Diagnosis of oral lichen planus: a position paper of the American Academy of Oral

and Maxillofacial Pathology. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122:332-54.

6. Gondivkar SM, Gadbail AR, Gondivkar RS, Sarode SC, Sarode GS, Patil S. Impact of oral potentially malignant disorders on quality of life: a systematic review. Future Oncol. 2018;14:995-1010.

7. Kramer IR, Lucas RB, Pindborg JJ, Sobin LH. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol. 1978;46:518-39.

8. van der Meij EH, van der Waal I. Lack of clinicopathologic correlation in the diagnosis of oral lichen planus based on the presently available diagnostic criteria and suggestions for modifications. J Oral Pathol Med. 2003;32:507-12.

9. Gorouhi F, Davari P, Fazel N. Cutaneous and mucosal lichen planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis. ScientificWorldJournal. 2014;2014:742826.

10. Kurago ZB. Etiology and pathogenesis of oral lichen planus: an overview. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122:72-80.

11.Zucoloto ML, Shibakura MEW, Pavanin JV, Garcia FT, da Silva Santos PS, Maciel AP, et al. Severity of oral lichen planus and oral lichenoid lesions is associated with anxiety. Clin Oral Investig. 2019;23:4441-4448.

12. Alves MG, do Carmo Carvalho BF, Balducci I, Cabral LA, Nicodemo D, Almeida JD. Emotional assessment of patients with oral lichen planus. Int J Dermatol. 2015;54:29-32.

13. Karbach J, Al-Nawas B, Moergel M, Daubländer M. Oral health-related quality of life of patients with oral lichen planus, oral leukoplakia, or oral squamous cell carcinoma. J Oral Maxillofac Surg. 2014;72:1517-22.

14. López-Jornet P, Camacho-Alonso F. Quality of life in patients with oral lichen planus. J Eval Clin Pract. 2010;16:111-3.

15. Corrêa JD, Branco LGA, Calderaro DC, Mendonça SMS, Travassos DV, Ferreira GA, et al. Impact of systemic lupus erythematosus on oral health-related quality of life. Lupus. 2018;27:283-9.

16. Yamanaka Y, Yamashita M, Innocentini LMA, Macedo LD, Chahud F, Ribeiro-Silva A, et al. Direct Immunofluorescence as a Helpful Tool for the Differential Diagnosis of Oral Lichen Planus and Oral Lichenoid Lesions. Am J Dermatopathol. 2018;40:491-7.

17. Varghese SS, George GB, Sarojini SB, Vinod S, Mathew P, Mathew DG, et al. Epidemiology of Oral Lichen Planus in a Cohort of South Indian Population: A Retrospective Study. J Cancer Prev. 2016;21:55-9.

18. Vučićević Boras V, Savage NW, Brailo V, Škrinjar I, Valter K, Alajbeg I, et al. The significance of oral and systemic factors in Australian and Croatian patients with oral lichen planus. Acta Dermatovenerol Croat. 2014;22:97-102.

19. Chainani-Wu N, Silverman S Jr, Lozada-Nur F, Mayer P, Watson JJ. Oral lichen planus: patient profile, disease progression and treatment responses. J Am Dent Assoc. 2001;132:901-9.

20. Boñar-Alvarez P, Pérez Sayáns M, Garcia-Garcia A, Chamorro-Petronacci C, Gándara-Vila P, Luces-González R, et al. Correlation between clinical and pathological features of oral lichen planus: A retrospective observational study. Medicine (Baltimore). 2019;98:14614.

21. Oliveira Alves MG, Almeida JD, Balducci I, Guimarães Cabral LA. Oral lichen planus: A retrospective study of 110 Brazilian patients. BMC Res Notes. 2010;3:157.

22. Barbosa NG, Silveira ÉJ, Lima EN, Oliveira PT, Soares MS, de Medeiros AM. Factors associated with clinical characteristics and symptoms in a case series of oral lichen planus. Int J Dermatol. 2015;54:1-6.

23. Werneck JT, Costa TO, Stibich CA, Leite CA, Dias EP, Silva Junior A. Oral lichen planus: study of 21 cases. An Bras Dermatol. 2015;90:321-6.

24. Knottnerus A, Tugwell P. STROBE--a checklist to Strengthen the Reporting of Observational Studies in Epidemiology. J Clin Epidemiol. 2008;61:323.

25. de Oliveira BH, Nadanovsky P. Psychometric properties of the Brazilian version of the Oral Health Impact Profile-short form. Community Dent Oral Epidemiol. 2005;33:307-14.

26. Lodi G, Carrozzo M, Furness S, Thongprasom K. Interventions for treating oral lichen planus: a systematic review. Br J Dermatol. 2012;166:938-47.

27. Fitzpatrick SG, Hirsch SA, Gordon SC. The malignant transformation of oral lichen planus and oral lichenoid lesions: a systematic review. J Am Dent Assoc. 2014;145:45-56.

28. Giuliani M, Troiano G, Cordaro M, Corsalini M, Gioco G, Lo Muzio L, et al. Rate of malignant transformation of oral lichen planus: A systematic review. Oral Dis. 2019;25:693-709.

29. Aghbari SMH, Abushouk AI, Attia A, Elmaraezy A, Menshawy A, Ahmed MS, et al. Malignant transformation of oral lichen planus and oral lichenoid lesions: A meta-analysis of 20095 patient data. Oral Oncol. 2017;68:92-102.

#### Acknowledgements

This study was supported by the Brazilian National Council for Scientific and Technological Development (CNPq, #401610/2016-0). A.C.B., E.F.M. and R.A.M. are research fellows at CNPq. The authors thank the Coordination for the Improvement of Higher Education Personnel (CAPES, Finance code 001) and Foundation for Research Support in the State of Goiás (FAPEG). J.A.A.A. and S.L.G.L. are the recipient of fellowship. Mrs. E. Greene provided English editing of the manuscript.

#### **Conflicts of Interest**

The authors do not have any conflicts of interest.